Intravitreous CytokinE Level in pAtient With retiNal Detachment
NCT ID: NCT03318588
Last Updated: 2022-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
74 participants
OBSERVATIONAL
2017-11-15
2018-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Physiologically, microglial cells (resident macrophages) are present only in the inner retina. The subretinal space, located between the retinal pigment epithelium (RPE) and the photoreceptor outer segments (POS), is devoid of all mononuclear phagocytes and form a zone of immune privilege. In AMD, several studies showed a strong association between subretinal mononuclear phagocytes infiltration and advanced forms of AMD. Experimental work in mice suggest that this infiltration plays an important role in the pathogenesis of this condition by producing inflammatory cytokines.
RD-induced photoreceptor apoptosis might result from similar mechanisms. The aim of this study is to determine the cytokine profile in vitreous samples from patients with RD and to compare it with those from control patients with macular hole.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Primary Vitrectomy for the Treatment of Retinal Detachment in Highly Myopic
NCT01480505
Internal Limiting Membrane Peeling in Retinal Detachment Surgery
NCT05538156
Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment
NCT06347302
The Role of Intravitreal Glucose in Macular Thinning Following Surgery for Retinal Detachment or Epimacular Membrane
NCT02210481
Clinical Characteristics and Surgical Outcomes of the Fellow Eye in Bilateral Retinal Detachments
NCT06292572
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case
Patients undergoing vitrectomy for primary retinal detachment
Vitrectomy
Pars plana vitrectomy
Control
Patients undergoing vitrectomy for idiopathic macular hole
Vitrectomy
Pars plana vitrectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitrectomy
Pars plana vitrectomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with idiopathic macular hole requiring vitrectomy
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Docteur Jean-Baptiste CONART
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Baptiste CONART, MD
Role: PRINCIPAL_INVESTIGATOR
Brabois Hospital, Department of Ophthalmology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brabois Hospital
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Conart JB, Blot G, Augustin S, Millet-Puel G, Roubeix C, Beguier F, Charles-Messance H, Touhami S, Sahel JA, Berrod JP, Leveillard T, Guillonneau X, Delarasse C, Sennlaub F. Insulin inhibits inflammation-induced cone death in retinal detachment. J Neuroinflammation. 2020 Nov 26;17(1):358. doi: 10.1186/s12974-020-02039-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02195-48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.